2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Monday, November 14, 2016

9:00AM-11:00AM: Abstract Number: 1487

Comparison Between Intima-Media Thickness and Coronary Artery Tomography in Subclinical Atheroesclerosis Detection in Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1728

Comparison of Adherence to Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis and Other Rheumatic Disease

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1289

Comparison of Clinical Parameters and PET/MRI in Juvenile Idiopathic Arthritis

Imaging of Rheumatic Diseases - Poster II: XR/CT/PET/MRI

9:00AM-11:00AM: Abstract Number: 1220

Comparison of Healthcare Utilization of Patients with Rheumatoid Arthritis Who Are Anti-Cyclic Citrullinated Peptide Antibody Positive Versus Negative

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1371

Comparison of Patient and Physician Reported Global Disease Activity Measures in Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1245

Comparison of Secukinumab Vs Adalimumab in a Cost per Responder Analysis Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Psoriatic Arthritis at 48 Weeks from the US Perspective

Health Services Research - Poster II

9:00AM-11:00AM: Abstract Number: 1372

Comparison of the Printo 2010 and Printo/International Myositis and Clinical Studies Group (IMACS) 2016 Improvement Criteria in the Printo Trial in New Onset Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1384

Comparison of the Systemic Lupus Collaborating Clinics-Damage Index Score with a Physician Global Assessment of Damage in an International Cohort of Patients with Childhood-Onset Systemic Lupus

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster II: Myositis, Systemic Lupus Erythematosus, Sjögren's Syndrome

9:00AM-11:00AM: Abstract Number: 1929

Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype

Vasculitis - Poster II: ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 1723

Composite Psoriatic Disease Activity Index (CPDAI), Defining Remission and Disease Activity States Using Data from Daily Clinical Practice

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

9:00AM-11:00AM: Abstract Number: 1500

Concomitant Development of Interstitial Pneumonia Associated with Dermatomyositis and Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

9:00AM-11:00AM: Abstract Number: 1134

Confidence and Competence of Medicine Trainees’ Musculoskeletal Skills: A Report of the Relationship from a Large Multi-Year, Multidisciplinary Cohort

Education - Poster

9:00AM-11:00AM: Abstract Number: 1877

Confirmatory Factor Analysis and Assessment of Differential Item Functioning of the Satisfaction with Appearance Scale in Systemic Sclerosis: A Comparison Across Sex, Race/Ethnicity and Disease Subtype

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster II

9:00AM-11:00AM: Abstract Number: 1630

Consistent Pharmacodynamic Effects of Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, on Serum Analytes Across Four Phase 3 Clinical Trials in Rheumatoid Arthritis

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster II

9:00AM-11:00AM: Abstract Number: 1704

Consistent Safety and Tolerability of Secukinumab over Long-Term Exposure in Patients with Active Psoriatic Arthritis and Moderate to Severe Plaque Psoriasis: Updated Pooled Safety Analyses

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster II: Psoriatic Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].